BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 17882284)

  • 61. Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma.
    Wilop S; van Gemmeren TB; Lentjes MH; van Engeland M; Herman JG; Brümmendorf TH; Jost E; Galm O
    Epigenetics; 2011 Aug; 6(8):1047-52. PubMed ID: 21934357
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.
    Kim JT; Li J; Jang ER; Gulhati P; Rychahou PG; Napier DL; Wang C; Weiss HL; Lee EY; Anthony L; Townsend CM; Liu C; Evers BM
    Carcinogenesis; 2013 May; 34(5):953-61. PubMed ID: 23354304
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epigenetic regulation of Wnt signaling pathway in urological cancer.
    Costa VL; Henrique R; Ribeiro FR; Carvalho JR; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
    Epigenetics; 2010 May; 5(4):343-51. PubMed ID: 20421722
    [TBL] [Abstract][Full Text] [Related]  

  • 64. DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients.
    Liu X; Fu J; Bi H; Ge A; Xia T; Liu Y; Sun H; Li D; Zhao Y
    BMC Cancer; 2019 Dec; 19(1):1212. PubMed ID: 31830937
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas.
    Chan SL; Cui Y; van Hasselt A; Li H; Srivastava G; Jin H; Ng KM; Wang Y; Lee KY; Tsao GS; Zhong S; Robertson KD; Rha SY; Chan AT; Tao Q
    Lab Invest; 2007 Jul; 87(7):644-50. PubMed ID: 17384664
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
    Tatetsu H; Ueno S; Hata H; Yamada Y; Takeya M; Mitsuya H; Tenen DG; Okuno Y
    Cancer Res; 2007 Jun; 67(11):5328-36. PubMed ID: 17545613
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Epigenetic silencing of LPP/miR-28 in multiple myeloma.
    Li Z; Wong KY; Chan GC; Chim CS
    J Clin Pathol; 2018 Mar; 71(3):253-258. PubMed ID: 28775176
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Methylation analysis of SFRP genes family in cervical adenocarcinoma.
    Lin YW; Chung MT; Lai HC; De Yan M; Shih YL; Chang CC; Yu MH
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1665-74. PubMed ID: 19513747
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor.
    Qi J; Zhu YQ; Luo J; Tao WH
    World J Gastroenterol; 2006 Nov; 12(44):7113-7. PubMed ID: 17131472
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma.
    Zhang Q; Wang LQ; Wong KY; Li ZY; Chim CS
    J Clin Pathol; 2015 Jul; 68(7):557-61. PubMed ID: 25855800
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Promoter methylation status of SFRP genes and induced apoptosis by demethylation in Jurkat cells].
    Xu C; Shen J; Liao B; Fu H; Zhou H; Qi Y; Huangfu Z; Chen Y; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):51-5. PubMed ID: 26876254
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway.
    Su HY; Lai HC; Lin YW; Liu CY; Chen CK; Chou YC; Lin SP; Lin WC; Lee HY; Yu MH
    Int J Cancer; 2010 Aug; 127(3):555-67. PubMed ID: 19957335
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.
    van Andel H; Kocemba KA; Spaargaren M; Pals ST
    Leukemia; 2019 May; 33(5):1063-1075. PubMed ID: 30770859
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Concurrent Hypermethylation of
    Wang H; Duan XL; Qi XL; Meng L; Xu YS; Wu T; Dai PG
    Mol Cells; 2017 Jan; 40(1):45-53. PubMed ID: 28152305
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.
    Yang ZQ; Liu G; Bollig-Fischer A; Haddad R; Tarca AL; Ethier SP
    Int J Cancer; 2009 Oct; 125(7):1613-21. PubMed ID: 19569235
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells.
    Xiang T; Li L; Yin X; Zhong L; Peng W; Qiu Z; Ren G; Tao Q
    J Cell Mol Med; 2013 Oct; 17(10):1236-46. PubMed ID: 23890219
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Wnt antagonist sFRP1 in colorectal tumorigenesis.
    Caldwell GM; Jones C; Gensberg K; Jan S; Hardy RG; Byrd P; Chughtai S; Wallis Y; Matthews GM; Morton DG
    Cancer Res; 2004 Feb; 64(3):883-8. PubMed ID: 14871816
    [TBL] [Abstract][Full Text] [Related]  

  • 78. MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3.
    Revet I; Huizenga G; Koster J; Volckmann R; van Sluis P; Versteeg R; Geerts D
    Cancer Lett; 2010 Mar; 289(2):195-207. PubMed ID: 19815336
    [TBL] [Abstract][Full Text] [Related]  

  • 79. SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
    García-Tobilla P; Solórzano SR; Salido-Guadarrama I; González-Covarrubias V; Morales-Montor G; Díaz-Otañez CE; Rodríguez-Dorantes M
    Gene; 2016 Nov; 593(2):292-301. PubMed ID: 27570179
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epigenetic silencing of SFRP5 promotes the metastasis and invasion of chondrosarcoma by expression inhibition and Wnt signaling pathway activation.
    Sheng W; Zhang ZC; Shi DY; Wang BC; Wu Q; Shao ZW; Yang SH; He TC; Liu JX
    Chem Biol Interact; 2018 Dec; 296():1-8. PubMed ID: 30125549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.